HSY - The Hershey Company Stock Analysis | Stock Taper
Logo
The Hershey Company

HSY

The Hershey Company NYSE
$194.03 -1.53% (-3.01)

Market Cap $39.36 B
52w High $239.48
52w Low $157.77
Dividend Yield 3.06%
Frequency Quarterly
P/E 36.13
Volume 1.35M
Outstanding Shares 202.84M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $3.1B $582.04M $435.11M 14.02% $2.19 $773.7M
Q4-2025 $3.09B $699.9M $320.02M 10.35% $1.62 $380.62M
Q3-2025 $3.18B $594.58M $276.32M 8.69% $1.36 $551.17M
Q2-2025 $2.61B $603.46M $62.72M 2.4% $0.31 $330.22M
Q1-2025 $2.81B $575.05M $224.2M 7.99% $1.11 $493.82M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $876.98M $13.84B $9.11B $4.73B
Q4-2025 $925.86M $13.74B $9.1B $4.64B
Q3-2025 $1.16B $13.58B $9.01B $4.56B
Q2-2025 $912.35M $13.65B $9.13B $4.51B
Q1-2025 $1.52B $13.97B $9.28B $4.68B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $435.11M $468.81M $-117.12M $-402.84M $-48.88M $354.21M
Q4-2025 $320.02M $926.55M $-896.53M $-266.92M $-237.16M $714.87M
Q3-2025 $276.32M $841.92M $-80.4M $-513.95M $250.67M $1.15B
Q2-2025 $62.72M $112.22M $-154.79M $-559.57M $-602.91M $-46.47M
Q1-2025 $224.2M $396.68M $-146.99M $537.08M $784.51M $251.16M

Revenue by Products

Product Q2-2025Q3-2025Q4-2025Q1-2026
North America Confectionery Segment
North America Confectionery Segment
$2.09Bn $2.62Bn $2.48Bn $2.49Bn
North America Salty Snacks Segment
North America Salty Snacks Segment
$320.00M $320.00M $360.00M $350.00M

Revenue by Geography

Region Q2-2025Q3-2025Q4-2025Q1-2026
International and Other Segment
International and Other Segment
$330.00M $380.00M $390.00M $390.00M
North America Segment
North America Segment
$2.29Bn $2.80Bn $2.70Bn $2.71Bn

Q1 2026 Earnings Call Summary

Read Call Summary

5-Year Trend Analysis

A comprehensive look at The Hershey Company's financial evolution and strategic trajectory over the past five years.

+ Strengths

Hershey combines a powerful portfolio of beloved brands with a leading market position in confectionery and a growing foothold in salty and better‑for‑you snacks. Revenue growth has been steady, cash generation from operations and free cash flow have been strong, and the balance sheet has gradually become more resilient with better liquidity and moderating leverage. Investments in automation, supply chain, and digital capabilities, alongside disciplined capital spending and shareholder returns, underscore a franchise that has historically converted brand strength into reliable cash flows.

! Risks

The most immediate concern is the sharp deterioration in profitability and margins in the latest year despite record revenue, which raises questions about the sustainability of past earnings levels. Elevated, though improving, debt, growing goodwill and intangibles from acquisitions, and the abrupt reset of retained earnings introduce financial and accounting uncertainties. Strategically, Hershey must manage exposure to volatile commodity costs, changing consumer preferences around health and sugar, intense competition, and the execution risk of integrating multiple snack acquisitions while maintaining the strength of its legacy brands.

Outlook

The company’s future trajectory hinges on its ability to rebuild margins while sustaining revenue growth. If cost pressures, commodity spikes, and integration expenses prove largely temporary and Hershey can leverage its scale, pricing power, and supply‑chain initiatives to restore prior profitability, the combination of strong brands and solid cash generation could remain attractive. If, however, the 2025 margin reset reflects a more structural shift to lower profitability, then the business may be entering a phase where growth is higher quality on the top line but less rewarding at the bottom line. Monitoring margin recovery, the performance of acquired snack brands, and the balance between reinvestment, debt management, and shareholder returns will be critical to assessing the medium‑term outlook.